Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, induces sleep via the b

来源 :中国睡眠研究会第7届全国学术年会暨2012金陵国际睡眠医学论坛 | 被引量 : 0次 | 上传用户:pingli_lp
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Magnolol, an active ingredient of the bark of Magnolia officinalis, has been reported to exert potent anti-epileptic effects via the GABAA receptor.The receptor also mediates sleep in humans and animals.The aim of this study was to determine whether magnolol could modulate sleep behaviors by recording EEG and electromyogram in mice.The results showed that magnolol administered i.p.at a dose of 5 or 25 mg/kg could significantly shorten the sleep latency, increase the amount of non-rapid eye movement (non-REM, NREM) and rapid eye movement (REM) sleep for 3 h after administration with an increase in the number of NREM and REM sleep episodes.
其他文献
会议
会议
会议
First night effect (FNE), a well-known phenomenon in human, is characterized by longer sleep latency and decreased total sleep time, which results from a subjects lack of adaptation to the unfamiliar
会议
Background: Neurobiological mechanisms underlying insomnia are poorly understood.Previous findings indicated that dysfunction of the emotional circuit might contribute to the neurobiological mechanism
会议
Objectives The morphology, neurochemical properties and axon projections of the neurons expressing adenosine A2A receptor (A2AR) in the mouse nucleus accumbens (NAc) were investigated to understand th
会议
Insomnia is a common problem for people with neuropathic pain.Therapies that not only reduce pain, but also improve sleep can provide multiple benefits without the risk of increased side effects for s
Electroacupuncture (EA) has been used to treat menopausal insomnia due to its significant efficacy in clinic.Because there is a lack of animal model of menopausal insomnia and scientific evaluation to
会议
GABA transporter subtype 1 (GAT1) constructs high affinity reuptake sites for GABA in the CNS and regulates GABAergic transmission.Compounds that inhibit GAT1 are targets for epilepsy treatment.Sedati
会议
Difficulties formulating comprehensive approaches to treat sleep-related diseases persist because the physiological mechanisms underlying sleep-wake regulation remain unclear.We employed gene-manipula
会议